GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » EV-to-EBITDA

Oncodesign Precision Medicine (XPAR:ALOPM) EV-to-EBITDA : -1.07 (As of Jun. 28, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncodesign Precision Medicine's enterprise value is €7.79 Mil. Oncodesign Precision Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.26 Mil. Therefore, Oncodesign Precision Medicine's EV-to-EBITDA for today is -1.07.

The historical rank and industry rank for Oncodesign Precision Medicine's EV-to-EBITDA or its related term are showing as below:

XPAR:ALOPM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.03   Med: -2.28   Max: -0.62
Current: -1.07

During the past 5 years, the highest EV-to-EBITDA of Oncodesign Precision Medicine was -0.62. The lowest was -20.03. And the median was -2.28.

XPAR:ALOPM's EV-to-EBITDA is ranked worse than
100% of 481 companies
in the Biotechnology industry
Industry Median: 8.87 vs XPAR:ALOPM: -1.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-28), Oncodesign Precision Medicine's stock price is €0.302. Oncodesign Precision Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.397. Therefore, Oncodesign Precision Medicine's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Oncodesign Precision Medicine EV-to-EBITDA Historical Data

The historical data trend for Oncodesign Precision Medicine's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine EV-to-EBITDA Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
- - -12.09 -3.02 -2.10

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial -12.09 - -3.02 - -2.10

Competitive Comparison of Oncodesign Precision Medicine's EV-to-EBITDA

For the Biotechnology subindustry, Oncodesign Precision Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's EV-to-EBITDA falls into.


;
;

Oncodesign Precision Medicine EV-to-EBITDA Calculation

Oncodesign Precision Medicine's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7.790/-7.264
=-1.07

Oncodesign Precision Medicine's current Enterprise Value is €7.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncodesign Precision Medicine  (XPAR:ALOPM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Oncodesign Precision Medicine's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.302/-0.397
=At Loss

Oncodesign Precision Medicine's share price for today is €0.302.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.397.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Oncodesign Precision Medicine EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines